Skip to main content
SpringerLink
Log in

Aclidinium

In Chronic Obstructive Pulmonary Disease

  • Adis Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Aclidinium, an inhaled, long-acting antimuscarinic agent, has been developed as a twice-daily maintenance treatment for chronic obstructive pulmonary disease (COPD).

Treatment with the approved dosage of aclidinium (400 μg twice daily) statistically significantly improved bronchodilation, disease-specific health status, dyspnoea, night-time COPD symptoms and use of rescue medication compared with placebo in pivotal studies of 12 (ACCORD COPD I) or 24 (ATTAIN) weeks duration in patients with moderate to severe COPD.

The improvements in bronchodilation, health status and dyspnoea were clinically meaningful compared with placebo after 24 weeks of treatment in ATTAIN; generally similar results were seen after 12 weeks of treatment in both trials.

Aclidinium also statistically significantly reduced the incidence of COPD exacerbations compared with placebo in these studies (albeit neither trial was designed to assess exacerbation frequency).

Inhaled aclidinium has a low systemic bioavailability; the approved dosage was generally well tolerated in clinical trials of up to 52 weeks duration.

Aclidinium had an adverse event profile that was similar to that of placebo and characterized by low incidences of major adverse cardiovascular events and potential anticholinergic adverse events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI

Similar content being viewed by others

References

  1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007 Sep 15; 176 (6): 532–55

    Article  PubMed  Google Scholar 

  2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (revised 2011) [online]. Available from URL: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdf [Accessed 2012 Jun 14]

  3. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007 Sep 1; 370 (9589): 765–73

    Article  PubMed  Google Scholar 

  4. Barnes PJ. New therapies for chronic obstructive pulmonary disease. Med Princ Pract 2010 Jul; 19 (5): 330–8

    Article  PubMed  Google Scholar 

  5. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir J 2009 Sep; 34 (3): 757–69

    Article  PubMed  CAS  Google Scholar 

  6. Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012 Jul; 64 (3): 450–504

    Article  PubMed  CAS  Google Scholar 

  7. Jones PW, Rennard SI, Agusti A, et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res 2011; 12: 55

    Article  PubMed  CAS  Google Scholar 

  8. Joos GF, Schelfhout VJ, Pauwels RA, et al. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients. Respir Med 2010 Jun; 104 (6): 865–72

    Article  PubMed  CAS  Google Scholar 

  9. Jansat JM, Lamarca R, Garcia Gil E, et al. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int J Clin Pharmacol Ther 2009 Jul; 47 (7): 460–8

    PubMed  CAS  Google Scholar 

  10. Chrystyn H, Niederlaender C. The Genuair® inhaler: a novel, multidose dry powder inhaler. Int J Clin Pract 2012 Mar; 66 (3): 309–17

    Article  PubMed  CAS  Google Scholar 

  11. Gavalda A, Miralpeix M, Ramos I, et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther 2009 Nov; 331 (2): 740–51

    Article  PubMed  CAS  Google Scholar 

  12. Lieberman JA 3rd. Managing anticholinergic side effects. Prim Care Companion J Clin Psychiatry 2004; 6 Suppl. 2: 20–3

    PubMed  Google Scholar 

  13. Lee TA, Pickard AS, Au DH, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008; 149: 380–90

    Article  PubMed  Google Scholar 

  14. Milara J, Serrano A, Peiro T, et al. Aclidinium inhibits human lung fibroblast to myofibroblast transition. Thorax 2012 Mar; 67 (3): 229–37

    Article  PubMed  Google Scholar 

  15. Cortijo J, Mata M, Milara J, et al. Aclidinium inhibits cholinergic and tobacco smoke-induced MUC5AC in human airways. Eur Respir J 2011 01 Feb; 37 (2): 244–54

    Article  PubMed  CAS  Google Scholar 

  16. Cortijo J, Milara J, Peiro T, et al. Cigarette smoke-induced fibroblast activation is attenuated by aclidinium in vitro [abstract]. Am J Respir Crit Care Med 183; 2011: A3596 [online]. Available from URL: http://ajrccm.atsjournals.org [Accessed 2012 Jun 18]

    Google Scholar 

  17. Dominguez-Fandos D, Puig-Pey R, Ferrer E, et al. Effects of aclidinium bromide on airway remodeling in guinea pigs exposed to cigarette smoke for 6 months [abstract]. Am J Respir Crit Care Med 183; 2011: A3595 [online]. Available from URL: http://ajrccm.atsjournals.org [Accessed 2012 Jun 18]

    Google Scholar 

  18. Singh D, Magnussen H, Kirsten A, et al. A randomized, placebo- and active-controlled dose finding study of aclidinium bromide administered twice a day in COPD patients. Pulm Pharmacol Ther 2012 Jun; 25 (3): 248–53

    Article  PubMed  CAS  Google Scholar 

  19. Chanez P, Burge PS, Dahl R, et al. Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm Pharmacol Ther 2010 Feb; 23 (1): 15–21

    Article  PubMed  CAS  Google Scholar 

  20. Vestbo J, Vogelmeier C, Creemers J, et al. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. COPD 2010 Sep; 7 (5): 331–6

    Article  PubMed  Google Scholar 

  21. Fuhr R, Magnussen H, Sarem K, et al. Efficacy of aclidinium bromide 400 mg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest 2012 Mar; 141 (3): 745–52

    Article  PubMed  CAS  Google Scholar 

  22. Donohue JF. Minimal clinically important differences in COPD lung function. COPD 2005 Mar; 2 (1): 111–24

    Article  PubMed  Google Scholar 

  23. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008 Feb; 31 (2): 416–69

    Article  PubMed  CAS  Google Scholar 

  24. Maltais F, Celli B, Casaburi R, et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med 2011 Apr; 105 (4): 580–7

    Article  PubMed  Google Scholar 

  25. Lasseter KC, Aubets J, Chuecos F, et al. Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects. J Clin Pharmacol 2011 Jun; 51 (6): 923–32

    Article  PubMed  CAS  Google Scholar 

  26. Almirall, S.A. Eklira Genuair 322 micrograms inhalation powder: summary of product characteristics. [online]. Available from URL: http://ec.europa.eu [Accessed 2012 Aug 23]

  27. Forest Pharmaceuticals, Inc. Tudorza™ Pressair™ (aclidinium bromide inhalation powder): US precribing information [online]. Available from URL: http://www.frx.com/pi/tudorza_pi.pdf [Accessed 2012 Aug 23]

  28. Jansat JM, Lamarca R, De Miquel G, et al. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. J Clin Pharmacol 2009 Oct; 49 (10): 1239–46

    Article  PubMed  CAS  Google Scholar 

  29. Lasseter K, Dilzer S, Jansat JM, et al. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers. Pulm Pharmacol Ther 2012 Apr; 25 (2): 193–9

    Article  PubMed  CAS  Google Scholar 

  30. Ortiz S, Flach S, Caracta C, et al. Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants. J Clin Pharmacol 2012 Jun; 52 (6): 819–27

    Article  PubMed  CAS  Google Scholar 

  31. Ortiz S, Flach S, Ho J, et al. Mass balance and metabolism of aclidinium bromide following intravenous administration of [14C]-aclidinium bromide in healthy subjects. Biopharm Drug Dispos 2012 Jan; 33 (1): 39–45

    Article  PubMed  CAS  Google Scholar 

  32. Newman SP, Sutton DJ, Segarra R, et al. Lung deposition of aclidinium bromide from Genuair®, a multidose dry powder inhaler. Respiration 2009; 78 (3): 322–8

    Article  PubMed  CAS  Google Scholar 

  33. de la Motte S, Beier J, Schmid K, et al. Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease. Int J Clin Pharm Ther 2012 May 22; 50 (6): 403–12

    Google Scholar 

  34. Schmid K, Pascual S, Gil EG, et al. Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: a phase I, open-label, single-dose clinical trial. Clin Ther 2010 Sep; 32(10): 1798–812

    Article  PubMed  CAS  Google Scholar 

  35. US Food and Drug Administration. Pulmonary Allergy Drugs Advisory Committee Meeting, February 23, 2012. NDA 202–450: aclidinium bromide for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including bronchitis and emphysema [online]. Available from URL: http://www.fda.gov [Accessed 2012 Aug 23]

  36. Prat M, Fernandez D, Buil MA, et al. Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-[hydroxy (di-2-thienyl)acetyl]oxy-1 -(3-phenoxypropyl)-1 -azoniabicyclo[2.2.2]octane bromide (aclidinium bromide). J Med Chem 2009 Aug 27; 52 (16): 5076–92

    Article  PubMed  CAS  Google Scholar 

  37. Sentellas S, Ramos I, Alberti J, et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci 2010 Mar 18; 39 (5): 283–90

    Article  PubMed  CAS  Google Scholar 

  38. Alberti J, Martinet A, Sentellas S, et al. Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide. Drug Metab Dispos 2010 Jul; 38 (7): 1202–10

    Article  PubMed  CAS  Google Scholar 

  39. Alberti JJ, Sentellas S, Salva M. In vitro liver metabolism of aclidinium bromide in preclinical animal species and humans: identification of the human enzymes involved in its oxidative metabolism. Biochem Pharmacol 2011 Mar 15; 81 (6): 761–76

    Article  PubMed  CAS  Google Scholar 

  40. Kerwin EM, D’Urzo AD, Gelb AF, et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012 Apr; 9 (2): 90–101

    Article  PubMed  Google Scholar 

  41. Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. Epub 2012 Mar 22

  42. Jones P, Agusti A, Bateman E, et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in symptoms and health status in the ATTAIN study [abstract]. Chest 2011; 140 (4_MeetingAbstracts): 547A [online]. Available from URL: http://journal.publications.chestnet.org/article.aspx?articleid=1046335 [Accessed 2012 Jun 18]

  43. Jones P, Singh D, Agusti A, et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): reduction in exacerbations as defined by healthcare utilization and the EXACT diary card [abstract]. Chest 2011; 140 (4_MeetingAbstracts): 529A [online]. Available from URL: http://journal.publications.chestnet.org/article.aspx?articleid=1045694 [Accessed 2012 Jun 18]

  44. Forest Research Institute, Inc. Aclidinium bromide in chronic obstructive pulmonary disease NDA 202450. FDA advisory briefing document [online]. Available from URL: http://www.fda.gov [Accessed 2012 Jun 6]

  45. Data on file, Forest Research Institute, 2012

  46. Gelb AF, Make BJ, Tashkin DP, et al. Long-term efficacy and safety of twice-daily aclidinium bromide in COPD patients: a one-year study [abstract]. Am J Respir Crit Care Med 185; 2012: A2256 [online]. Available from URL: http://ajrccm.atsjournals.org [Accessed 2012 Jun 18]

    Google Scholar 

  47. D’Urzo AD, Kerwin EM, Donohue JF, et al. Long-term extension study of ACCORD COPD I: effects of two doses of twice daily aclidinium bromide in COPD patients [abstract]. Am J Respir Crit Care Med 185; 2012: A2913 [online]. Available from URL: http://ajrccm.atsjournals.org [Accessed 2012 Jun 18]

    Google Scholar 

  48. Hass C, Engdahl K, Albert W, et al. Patient preferences and perceived ease of use in inhaler features: Genuair vs other inhalers [abstract]. Chest 2010; 138 (4_MeetingsAbstracts): 484A [online]. Available from URL: http://journal.publications.chestnet.org/mobile/article.aspx?articleid=1087181 [Accessed 2012 Jun 18]

  49. Almirall, S.A./Forest Laboratories. Long-term efficacy and safety of aclidinium/formoterol fixed-dose combination [ClinicalTrials.gov identifier NCT01462942]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2012 Jul 16]

  50. Forest Laboratories/Almirall, S.A. Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28-weeks treatment in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD) [ClinicalTrials.gov identifier NCT01572792]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2012 Jul 16]

  51. Forest Laboratories/Almirall, S.A. Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC) [ClinicalTrials.gov identifier NCT01437397]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2012 Jul 16]

  52. Forest Laboratories/Almirall, S.A. Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC) [ClinicalTrials.gov identifier NCT0 1437540]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2012 Jul 16]

Download references

Acknowledgements and Disclosures

The manuscript was reviewed by M. Cazzola, Division of Respiratory Diseases, Department of Internal Medicine, University of Rome, Rome, Italy; A.D. D’ Urzo, Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada; H. Magnussen, Pulmonary Research Institute at Hospital Grosshansdorf, Center for Pneumology and Thoracic Surgery, Grosshansdorf, Germany.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    James E. Frampton

Authors
  1. James E. Frampton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James E. Frampton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frampton, J.E. Aclidinium. Drugs 72, 1999–2011 (2012). https://doi.org/10.2165/11209700-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11209700-000000000-00000

Keywords

Search

Navigation